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Objective: Glutamine has been shown to promote heat shock protein 70 (HSP70) release both within
experimental in vitro models of sepsis (2e10 mM) and in adults post trauma (0.5 g/kg), although the
efﬁcacy varies and is dependent on the model used. The effect of glutamine supplementation on HSP70
release in children is less clear. Therefore, the aim of this study was to investigate the effect of 2 mM
glutamine added to incubation media on HSP70 and inﬂammatory mediator release in an in vitro model
of paediatric sepsis using whole blood from healthy paediatric volunteers.
Methods: An in vitro whole blood endotoxin stimulation model using 1 mg/ml lipopolysaccharide (LPS)
over a 24 h time period was used to investigate the effects of 2 mM glutamine on HSP70 and inﬂam-
matory mediator release in healthy children.
Results: The addition of 2 mM glutamine to the incubation media signiﬁcantly increased HSP70 release
over time (p < 0.05). This was associated with an early pro-inﬂammatory effect on TNF-a release at
4 h (p < 0.005) which was not seen at 24 h. There was a non signiﬁcant trend towards higher levels of IL-
6 and IL-10 following the addition of 2 mM glutamine, which appears to differ from the response re-
ported in adult and animal models.
Conclusion: Glutamine supplementation of incubation media promotes HSP70 and early TNF- a release
in an in vitro model using blood samples from healthy children.
© 2014 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.What is known:
 The addition of glutamine to incubation media promotes
HSP70 release in in vitro experimental models of sepsis.
 During times of infection, HSP70 release signals via cell
surface ligands TLR2 and 4 activating inflammatory
pathway of NF-KB promoting the release of inflammatory
mediators.nd Dietetics, University Hos-
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ical Nutrition (2014), http://What this study adds:
 The addition of 2 mM glutamine to incubation media in a
paediatric in vitro model of sepsis significantly increased
HSP70 levels over time.
 The addition of 2 mM glutamine to incubation media
appeared to promote an early pro-inflammatory response
in a paediatric model of sepsis.
1. Introduction
HSP70 forms part of the cellular response to stress [1]. Levels of
extracellular HSP70 are increased, in response to infection, forming
a network of molecules discharged by stressed or damaged cells
[2,3]. HSP70 has powerful immunoregulatory effects [4e7],
providing cellular protection [8] preventing apoptosis and cell
death [9e13]. Under normal circumstances HSP70 is detectable inism. All rights reserved.
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mation), suggesting that during times of homeostasis, HSP70 does
not promote an inﬂammatory response and its immunoregulatory/
inﬂammatory functions are tightly controlled [3]. However, during
times of stress HSP70 is able to interact with antigen presenting
cells (APC's) and activate both innate as well as adaptive immunity.
The type of response elicited depends on whether HSP70 is within
or external to the cell, the particular cell surface receptor sites it
binds to [14] and the type of T cells stimulated. In experimental
model of sepsis, in vitro cell culture models HSP70 has been shown
to signal via the Toll like receptors (TLR) 2/4-MyD88-nuclear factor
kappa B (NF-kB) pathway promoting the release of inﬂammatory
mediators [15] inﬂuencing the mix of cytokines released [3]. As the
stress response resolves, HSP70 acts to dampen down the inﬂam-
matory and immunoregulatory response, restoring cellular ho-
meostasis [16,17].
As such the effects of HSP70 appear to be dependent of the
model used (e.g. cell culture, animal, human). A recent analysis
considering the effect of HSP70 in animal models compared to
humans indicate that whilst HSP70 confers an almost entirely
protective effect in animals (97.1%) the same may not be true in
humans, with only a 50% protective effect demonstrated [1].
Therefore the clinical beneﬁt of HSP70 upregulation during times of
stress remains unclear, especially as both low and high levels in
children and adults are associated with increased risk in children
and adults mortality and infection risk [1,18]. In adults following
trauma HSP70 levels 15 ng/ml is associated with increased mor-
tality [19], conversely, levels60 ng/ml is associatedwith increased
mortality in traumatic brain injury [20] and severe sepsis in adults
[21] and children [22]. Our own work in children with acute
meningococcal disease, found signiﬁcantly higher levels of HSP70
in the acute phase of illness, although this were not associated with
increased mortality [23].
Glutamine, as a modulator of the heat shock response [24] is
well described in experimental models of sepsis [25] and in adults
following trauma [26]. Glutamine exerts a complex regulatory ac-
tivity with respect to the activation of intracellular signalling
pathways associated with inﬂammation and can inﬂuence the
milieu of inﬂammatory mediator release in response to stress
independently of HSP70 [27,28].
We have previously shown that glutamine depletion occurs in
critically ill children and is correlated with length of stay and illness
severity scores [23]. There is, however, limited information
regarding the effect of glutamine supplementation on the HSP70
and inﬂammatory mediator release in children [29]. As such we
sought to investigate the in vitro effects of endotoxin and glutamine
on HSP70 release and its association with markers of inﬂammatory
response, using an in vitrowhole blood model in healthy paediatric
volunteers. As HSP70 is produced by a large variety of cells
including granulocytes and peripheral mononuclear cells [3] we
chose to use an in vitro whole blood endotoxin stimulation model.
Endotoxin has been used extensively to understand the patho-
physiological response to sepsis/stress as well as for the study of
cytokine [30] and HSP70 release [31], providing further insight into
the host response [32].
The aim of this study was to investigate the effect of the addition
of 2 mM glutamine to incubation media on HSP70 and inﬂamma-
tory mediator release in an in vitro model of paediatric sepsis.
2. Materials and methods
This study was approved by the St Mary's Hospital Imperial
College Foundation Trust (reference number EC3262). After
obtaining informed parental consent, 25 healthy children were
prospectively enrolled from a general paediatric outpatient clinic.Please cite this article in press as: Marino LV, et al., The effect of 2 mM
stimulated blood from healthy children, Clinical Nutrition (2014), http://Heparinised whole blood was diluted 1:1 with glutamine free RPMI
(Sigma Aldrich), stimulated with ± LPS (1 mg/ml) in duplicate, and
incubated at 37 C, 5% CO2. After 2 h of culture, 2mMglutaminewas
added to half the conditions and incubated for another 2 h and for a
further 22 h. At each time point (4 h and 24 h) supernatant was
removed, centrifuged for 10 min at 1200 g and immediately stored
at 80 C. HSP70 and inﬂammatory mediators were measured as
per manufacturer's instructions using High Sensitivity HSP70
(HSP72) ELISA (Enzo Life Sciences CA; USA) and MSD Human pro-
inﬂammatory e 3 II ultra sensitive ELISA (Meso Scale; MY; USA)
measuring inﬂammatory mediators IL-6, TNF-a and IL-10. As
plasma fromwhole blood in vitromodel was used, wewere not able
to discriminate between the source (e.g. granulocytes, lymphocytes
or peripheral mononuclear cells) and subsequent role of the HSP70
released from the in vitro cell mix.
Statistical analysis of clinical variables, HSP70 and cytokine data
was completed using statistical analysis package Graphpad Prism 4.0
for Windows (Graphpad Software, San Diego, CA) and Statistical
Package for Social Sciences 19.0 (SPSS: An IBMCompany, Chicago, IL).
3. Results
3.1. Effect of 2 mM glutamine on HSP70 release in endotoxin
stimulated whole blood from healthy paediatric volunteers
In children, the addition of 2 mM glutamine to incubationmedia
signiﬁcantly upregulated HSP70 release at 24 h in endotoxin
stimulated whole blood (p < 0.005) in comparison to conditions
with no glutamine (Fig. 1). In unstimulated blood, the release of
HPS70 was signiﬁcantly upregulated at 24 h in conditions with/
without glutamine compared to those at 4 h (p < 0.005) (Fig. 1).
The addition of 2 mM glutamine to incubation media with
endotoxin signiﬁcantly stimulated the release of TNF-a at
4 h (p < 0.05) but not at 24 h (Fig. 2). A similar effect was seenwith
IL-6, although this was not signiﬁcant (Fig. 3). 2 mM glutamine
appeared to have no effect on the release of IL-10 (Fig. 4). There was
a positive correlations between HSP70 and IL-6 (n ¼ 25, r ¼ 0.61,
p ¼ 0.004) and TNF-a (n ¼ 25, r ¼ 0.61, p ¼ 0.005) at 4 h following
the addition of 2 mM glutamine to incubation media (Fig. 5a and b)
but there was no relationship between HSP70 and IL-10 (n ¼ 25,
r ¼ 0.191, p ¼ 0.382).
4. Discussion
In an in vitro model of paediatric sepsis the addition of 2 mM
glutamine to incubation media signiﬁcantly increased HSP70
release at 24 h, concurring with other models of experimental
sepsis [25,33] and critically ill adults [26]. However, in addition, to
this we also found there was a signiﬁcant release of HSP70 in
unstimulated whole blood control wells with and without gluta-
mine. The signiﬁcant increase in HSP70 levels appears to be a
physiological response to the experimental conditions, and has
previously been described in vitro and in vivo studies [25,34e36]
and is unlikely to be due to endotoxin contamination given that
inﬂammatory mediator levels were low at each time point in
control wells. The addition of 2 mM glutamine to incubation media
in endotoxin stimulated blood from paediatric volunteers signiﬁ-
cantly increased the release of TNF-a at 4 h, although at 24 h the
release of TNF-a in endotoxin stimulated blood was not signiﬁ-
cantly different. Therewas a similar but non signiﬁcant trend for IL-
6 release after the addition of 2 mM glutamine to incubationmedia.
However, The addition of 2 mM glutamine had no discernible effect
on IL-10 at 4 or 24 h following endotoxin stimulation though it may
be that dosage greater than 2 mM glutamine is required to signif-
icantly inﬂuence the release of inﬂammatory mediators [37,38].ol glutamine supplementation on HSP70 and TNF-a release by LPS
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Fig. 1. The effect of 2 mM glutamine supplementation on LPS stimulated HSP70 release at 4 h and 24 h in whole blood from healthy paediatric volunteers (n ¼ 25). Results are
expressed as mean; ± SEM. Glutamine ¼ glutamine, LPS ¼ endotoxin **p < 0.005, ***p < 0.0005.
L.V. Marino et al. / Clinical Nutrition xxx (2014) 1e7 3The putative role of extracellular HSP70 during times of stress
in children has yet to clearly deﬁned, making it challenging to
interpret our results. It has been postulated that constitutive
levels of extracellular HSP70 in vivo help maintain immune ho-
meostasis through T regulatory cell control. During times of stress
high levels of HSP70 are released at sites of infection or tissue
damage resulting in a loss of T regulatory cell control contributingFig. 2. The effect of glutamine supplementation on endotoxin stimulated release of TNF-a i
expressed as mean; ± SEM. Glutamine ¼ glutamine, LPS ¼ endotoxin *p < 0.05, **p < 0.00
Please cite this article in press as: Marino LV, et al., The effect of 2 mM
stimulated blood from healthy children, Clinical Nutrition (2014), http://to a pro-inﬂammatory response, which reﬂects the response seen
in our in vitro model. As the stress response resolves and HSP70
levels decline T regulatory cell function is restored with a reso-
lution of the inﬂammatory response and return to homeostasis
[39,40].
HSP70 also appears to inﬂuence the mix of cytokines released,
which is dependent on the model used, for example an in vitron whole blood from healthy paediatric volunteers at 4 h and 24 h (n ¼ 25). Results are
5.
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Fig. 3. The effect of glutamine supplementation on endotoxin stimulated release of IL-6 in whole blood from healthy paediatric volunteers at 4 h and 24 h (n ¼ 25). Results are
expressed as mean; ± SEM. Glutamine ¼ glutamine, LPS ¼ endotoxin ***p < 0.0005.
L.V. Marino et al. / Clinical Nutrition xxx (2014) 1e74model of sepsis model using, either lipoteichoic acid or LPS, shows
that pre-treatment of human neutrophils with recombinant HSP70
prior to the administration of endotoxin attenuates the release of
TNF-a [41]. This is corroborated in other in vitro animal models
where the use of recombinant HSP70 provides a similar anti-Fig. 4. The effect of glutamine supplementation on endotoxin stimulated release of IL-10 in
expressed as mean; ± SEM. Glutamine ¼ glutamine, LPS ¼ endotoxin. *p ¼ 0.05, **p < 0.0
Please cite this article in press as: Marino LV, et al., The effect of 2 mM
stimulated blood from healthy children, Clinical Nutrition (2014), http://inﬂammatory mode of action by inhibiting C/EBPb and C/EPBd
transcription factors from signalling via TLR2-ERK-STAT2-1L10
pathway, attenuating the release of pro-inﬂammatory mediators
[42]. Converse to this, when healthy subjects were inoculated with
endotoxin, levels of HSP70 and proinﬂammatory mediatorswhole blood from healthy paediatric volunteers at 4 h and 24 h (n ¼ 25). Results are
05, ***p < 0.0005.
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Fig. 5. a) Graphical representation (scatter plot) correlations between the effect of
glutamine supplementation on endotoxin stimulated release of IL-6 in whole blood
from healthy paediatric volunteers at 4 h (n ¼ 25, r ¼ 0.61, p ¼ 0.004). b) Graphical
representation (scatter plot) correlations between the effect of glutamine supple-
mentation on endotoxin stimulated release of TNF-a in whole blood from healthy
paediatric volunteers at 4 h (n ¼ 25, r ¼ 0.61, p ¼ 0.005).
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pleiotropic effect of HSP70 was not established [31].
In our study the addition of 2 mM glutamine to incubation
media appeared to promote the release of pro-inﬂammatory me-
diators [43], which could be reﬂective of experimental conditions,
levels of extracellular HSP70 release or glutamine levels within the
in vitro model. The cellular response to infection is a complex
process co-ordinated by a wide range of intra- and extracellular
mediators. Within this dynamic, glutamine and HSP70 inﬂuence
and are inﬂuenced by, the mix of inﬂammatory mediators, acti-
vating protective cellular defencemechanisms [44], and a challenge
for the future is to elucidate whether there is any clinical relevance
of this in critically ill children.
Glutamine supplementation in children has yielded conﬂicting
results. In studies of glutamine supplementation in pre-term in-
fants [45e50], infants with gastrointestinal disease and surgery
[51,52], childrenwith burns [53,54] andmalnutrition [55e57], little
or no beneﬁt on survival, late onset sepsis or duration of hospital
stay have been described [18]. In addition recent evidence indicates
that either hypo-glutamine <430 mmol/L [58] or hyper-glutamine
levels >930 mmol/L are associated with increased mortality
[59,60]. The mechanism for the effect of supra physiological
glutamine levels on HSP70 release and inﬂammatory mediators in
critical illness is not known. However, an in vitro model of human
skeletal muscle linked supraphysiological levels of glutamine to
respiratory uncoupling and energy wasting within the mitochon-
driawhich was associatedwith cell death [61]. In addition, KrajcovaPlease cite this article in press as: Marino LV, et al., The effect of 2 mM
stimulated blood from healthy children, Clinical Nutrition (2014), http://et al. have suggested the hypoglutaminaemia seen during critical
illness may be a protective mechanism. They show that supra
physiological levels of glutamine decrease the efﬁciency of the
mitochondrial respiratory chain contributing to the bioenergetics
failure of the mitochondria (a feature of critical illness), where
engorged mitochondria are not able to meet adenosine tri phos-
phate demands of tissues, resulting in cell death [61]. As such the
hypoglutaminaemia described by us [23] and others during critical
illness [62], may be a protective mechanism decreasing mito-
chondrial size allowing for restoration and repair during the re-
covery phase [61].
Furthermore, it may also be the increased mortality seen in
these studies may be as a result of the metabolic decompensation
associated with sepsis/septic shock and multiorgan failure rather
than the effect of glutamine per se [59,60]. The effective modula-
tion and management of the inﬂammatory response to infection
remains elusive, as complete abrogation of inﬂammation and or
over stimulation results in increased mortality [63].
Our results suggest that the addition of 2 mM glutamine to in-
cubation media using an in vitro endotoxin model from whole
blood of healthy children, may promote increased levels of TNF-a,
and mediated via HSP70 release, although the clinical signiﬁcance
of this is not known. Since the results from Heyland and Dhaliwal
[64] describing the increased risk of mortality following the use of
glutamine in sepsis, supplementation is no longer recommended
[65]. Furthermore, the effect of glutamine supplementation has not
been elucidated in critically ill children and so its use cannot be
recommended in immune competent children [18]. Further work is
required to understand what the role of glutamine is in critically ill
children.
The conclusions from our work should be regarded with some
caution owing to certain limitations of the study, which include the
investigation of only one dose of glutamine (2 mM) that signiﬁ-
cantly upregulated HSP70 release in paediatric endotoxin stimu-
lation models. The effect of 2 mM glutamine on the release of
inﬂammatory mediators was less clear. It may be that a large dose
of glutamine (2mM) is required in the paediatric models to better
understand the effect of glutamine mediated HSP70 release and
subsequent milieu of inﬂammatory mediators. Although a range of
pro- and anti-inﬂammatory mediators were selected for study
based on previous work in meningococcal disease, it was not
possible to examine all those of interest within a single validated
multiplex plate as we were limited on blood volume available from
paediatric samples. Another limitation of our in vitro models was
the lack of discrimination between live and dead cells, which pre-
vented the source of HSP70 release (e.g. passive release or as a
result of necrosis) from being determined.5. Conclusion
These results would suggest that the addition of 2 mM gluta-
mine to incubation media promotes HSP70 release in an in vitro
endotoxin stimulation model in children. The results from this
work highlight the need to explore the relationships of glutamine,
HSP70 and inﬂammatory mediators further, particularly given the
conﬂicting reports of beneﬁt of glutamine during critical illness.
Given the current paucity of evidence regarding the efﬁcacy of
glutamine supplementation during paediatric critical illness and
sepsis it should not be given until the effects of supplementation on
the inﬂammatory response are better understood.Conﬂict of interest
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